Heather Johnson

Opthea, the Australia-based biopharma developing a novel therapy to treat exudative retinal diseases, closed out a busy summer with a US Securities and Exchange Commission ...

They won’t help you search the Internet, but Kubota Vision’s glasses may help slow the progression of myopia, and possibly even prevent the condition when ...

Ophthalmology drugs, particularly drugs associated with surgeries and retinal disease, took a beating in Q2 because of COVID-19 disruptions. Things may be looking up for ...

The glaucoma space has been dominated by a host of products designed to lower intraocular pressure (IOP) – minimally invasive glaucoma surgery (MIGS) devices and ...

Editor's Note: The FDA just approved Allergan's Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on ...

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make ...

SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device ...

SAN FRANCISCO – When it comes to securing reimbursement models, ophthalmic device and drug developers are facing mounting pressure. Payers are demanding more evidence on ...

SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs, ...